Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia
The DOI matches its Crossref record; 233 of the 233 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shi, Y., Yan, H., Frost, P., Gera, J., & Lichtenstein, A. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0068 · Cited by 368
RetractedPhosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Hayden, M. S., & Ghosh, S. (2004) · Genes & Development · doi:10.1101/gad.1228704 · Cited by 3,842
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
ROS stress in cancer cells and therapeutic implications
Pelicano, H., Carney, D., & Huang, P. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.01.004 · Cited by 2,006
The activation of Akt/PKB signaling pathway and cell survival
Song, G., Ouyang, G., & Bao, S. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00337.x · Cited by 1,888
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., & Birnbaum, M. J. (2001) · Science · doi:10.1126/science.292.5522.1728 · Cited by 1,836
Aggarwal, B. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.003 · Cited by 1,574
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Akt Stimulates Aerobic Glycolysis in Cancer Cells
Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., Zhuang, H., Cinalli, R. M., Alavi, A., Rudin, C. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2904 · Cited by 1,454
AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1
Medema, R. H., Kops, G. J. P. L., Bos, J. L., & Burgering, B. M. T. (2000) · Nature · doi:10.1038/35008115 · Cited by 1,438
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
FOXO transcription factors at the interface between longevity and tumor suppression
Greer, E. L., & Brunet, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209086 · Cited by 1,310
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
PI3K-Akt pathway: Its functions and alterations in human cancer
Osaki, M., Oshimura, M., & Ito, H. (2004) · Apoptosis · doi:10.1023/b:appt.0000045801.15585.dd · Cited by 1,264
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
PI3K/Akt and apoptosis: size matters
Franke, T. F., Hornik, C. P., Segev, L., Shostak, G. A., & Sugimoto, C. (2003) · Oncogene · doi:10.1038/sj.onc.1207115 · Cited by 1,184
Seoane, J., Le, H.-V., Shen, L., Anderson, S. A., & Massagué, J. (2004) · Cell · doi:10.1016/s0092-8674(04)00298-3 · Cited by 1,028
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene
Chen, W. S., Xu, P.-Z., Gottlob, K., Chen, M.-L., Sokol, K., Shiyanova, T., Roninson, I., Weng, W., Suzuki, R., Tobe, K., et al. (2001) · Genes & Development · doi:10.1101/gad.913901 · Cited by 928
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins
Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., & Pan, D. (2003) · Nature Cell Biology · doi:10.1038/ncb999 · Cited by 923
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Lin, Y.-Z., Yao, S., Veach, R. A., Torgerson, T. R., & Hawiger, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.24.14255 · Cited by 918
Gao, T., Furnari, F., & Newton, A. C. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.008 · Cited by 906
Basu, S., Totty, N. F., Irwin, M. S., Sudol, M., & Downward, J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(02)00776-1 · Cited by 843
Advances in protein kinase B signalling: AKTion on multiple fronts
Brazil, D. P., Yang, Z.-Z., & Hemmings, B. A. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.03.006 · Cited by 830
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821
PDK1, the master regulator of AGC kinase signal transduction
Mora, A., Komander, D., van Aalten, D. M. F., & Alessi, D. R. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2003.12.022 · Cited by 810
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
Guzman, M. L., Neering, S. J., Upchurch, D., Grimes, B., Howard, D. S., Rizzieri, D. A., Luger, S. M., & Jordan, C. T. (2001) · Blood · doi:10.1182/blood.v98.8.2301 · Cited by 758
Structure, regulation and function of PKB/AKT—a major therapeutic target
Hanada, M., Feng, J., & Hemmings, B. A. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.009 · Cited by 719
The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation
van der HEIDE, L. P., HOEKMAN, M. F. M., & SMIDT, M. P. (2004) · Biochemical Journal · doi:10.1042/bj20040167 · Cited by 691
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., & McCubrey, J. A. (2004) · Leukemia · doi:10.1038/sj.leu.2403241 · Cited by 684
Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells
Irish, J. M., Hovland, R., Krutzik, P. O., Perez, O. D., Bruserud, Ø., Gjertsen, B. T., & Nolan, G. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.028 · Cited by 684
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes
Hresko, R. C., & Mueckler, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 635
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A. P., et al. (2000) · PubMed · Cited by 620
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T. A., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00050-9 · Cited by 614
Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 591
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
West, K. A., Sianna Castillo, S., & Dennis, P. A. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00120-6 · Cited by 585
Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., Akiyama, T., Kuroda, H., Kawano, Y., Kobune, M., et al. (2003) · Nature Medicine · doi:10.1038/nm909 · Cited by 563
Krutzik, P. O., & Nolan, G. P. (2003) · Cytometry Part A · doi:10.1002/cyto.a.10072 · Cited by 562
Cell Cycle Inhibition by FoxO Forkhead Transcription Factors Involves Downregulation of Cyclin D
Schmidt, M., Fernandez de Mattos, S., van der Horst, A., Klompmaker, R., Kops, G. J. P. L., Lam, E. W.-F., Burgering, B. M. T., & Medema, R. H. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.22.7842-7852.2002 · Cited by 562
(2001) · PubMed · Cited by 557
Role for Akt3/Protein Kinase Bγ in Attainment of Normal Brain Size
Easton, R. M., Cho, H., Roovers, K., Shineman, D. W., Mizrahi, M., Forman, M. S., Lee, V. M.-Y., Szabolcs, M., de Jong, R., Oltersdorf, T., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1869-1878.2005 · Cited by 551
Garcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00051-0 · Cited by 542
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
Role of chemopreventive agents in cancer therapy
Dorai, T., & Aggarwal, B. B. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.07.013 · Cited by 529
Oncogenic PI3K and its role in cancer
Samuels, Y., & Ericson, K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198021.99347.b9 · Cited by 521
The Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
TOR Regulates Ribosomal Protein Gene Expression via PKA and the Forkhead Transcription Factor FHL1
Martin, D. E., Soulard, A., & Hall, M. N. (2004) · Cell · doi:10.1016/j.cell.2004.11.047 · Cited by 479
Mitsiades, C. S., Mitsiades, N., Poulaki, V., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Treon, S. P., Munshi, N. C., Richardson, P. G., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205664 · Cited by 464
Signalling by PI3K isoforms: insights from gene-targeted mice
Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B., & Foukas, L. C. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.02.008 · Cited by 444
Control of Cell Cycle Exit and Entry by Protein Kinase B-Regulated Forkhead Transcription Factors
Kops, G. J. P. L., Medema, R. H., Glassford, J., Essers, M. A. G., Dijkers, P. F., Coffer, P. J., Lam, E. W.-F., & Burgering, B. M. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2025-2036.2002 · Cited by 442
Glycogen Synthase Kinase-3β: A Novel Regulator of Cardiac Hypertrophy and Development
Hardt, S. E., & Sadoshima, J. (2002) · Circulation Research · doi:10.1161/01.res.0000018952.70505.f1 · Cited by 438
Targeting mTOR signaling for cancer therapy
Huang, S. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00071-7 · Cited by 436
Anto, R. J. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.143 · Cited by 429
A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR
Ramaswamy, S., Nakamura, N., Sansal, I., Bergeron, L., & Sellers, W. R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00086-7 · Cited by 428
PP2A: the expected tumor suppressor
Janssens, V., Goris, J., & Van Hoof, C. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.004 · Cited by 426
Preferential induction of apoptosis for primary human leukemic stem cells
Guzman, M. L., Swiderski, C. F., Howard, D. S., Grimes, B. A., Rossi, R. M., Szilvassy, S. J., & Jordan, C. T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252462599 · Cited by 426
Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3434 · Cited by 422
Vazquez, F., Grossman, S. R., Takahashi, Y., Rokas, M. V., Nakamura, N., & Sellers, W. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100556200 · Cited by 413
The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network
Mayo, L. D., & Donner, D. B. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02166-7 · Cited by 410
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. (2003) · PubMed · Cited by 407
Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells
Kuo, M.-L., Huang, T.-S., & Lin, J.-K. (1996) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(96)00032-4 · Cited by 404
Neckers, L., & Ivy, S. P. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00003 · Cited by 400
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Xu, Q., Simpson, S.-E., Scialla, T. J., Bagg, A., & Carroll, M. (2003) · Blood · doi:10.1182/blood-2002-11-3429 · Cited by 394
Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X.-M., Feldman, R. I., Hamilton, A. D., Polokoff, M., Nicosia, S. V., Herlyn, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0343 · Cited by 371
Taussig, D. C. (2005) · Blood · doi:10.1182/blood-2005-03-1072 · Cited by 370
Restraining PI3K: mTOR signalling goes back to the membrane
Harrington, L. S., Findlay, G. M., & Lamb, R. F. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.003 · Cited by 366
Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse
Kaufmann, S. H., Karp, J. E., Svingen, P. A., Krajewski, S., Burke, P. J., Gore, S. D., & Reed, J. C. (1998) · Blood · doi:10.1182/blood.v91.3.991 · Cited by 365
Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement
Sadhu, C., Masinovsky, B., Dick, K., Sowell, C. G., & Staunton, D. E. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2647 · Cited by 365
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Structure and regulation of Kit protein-tyrosine kinase—The stem cell factor receptor
Roskoski, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.150 · Cited by 345
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
Protein kinase CK2 phosphorylates and upregulates Akt/PKB
Di Maira, G., Salvi, M., Arrigoni, G., Marin, O., Sarno, S., Brustolon, F., Pinna, L. A., & Ruzzene, M. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401604 · Cited by 327
George, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W., Guo, F., Sigua, C., Sondarva, G., Moscinski, L., Atadja, P., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3413 · Cited by 324
Orlowski, R. Z., Voorhees, P. M., Garcia, R. A., Hall, M. D., Kudrik, F. J., Allred, T., Johri, A. R., Jones, P. E., Ivanova, A., Van Deventer, H. W., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2911 · Cited by 319
Estrov, Z., Shishodia, S., Faderl, S., Harris, D., Van, Q., Kantarjian, H. M., Talpaz, M., & Aggarwal, B. B. (2003) · Blood · doi:10.1182/blood-2002-11-3550 · Cited by 306
Müller-Tidow, C., Steffen, B., Cauvet, T., Tickenbrock, L., Ji, P., Diederichs, S., Sargin, B., Köhler, G., Stelljes, M., Puccetti, E., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2890-2904.2004 · Cited by 303
Antileukemic activity of rapamycin in acute myeloid leukemia
Récher, C., Beyne-Rauzy, O., Demur, C., Chicanne, G., Dos Santos, C., Mas, V. M.-D., Benzaquen, D., Laurent, G., Huguet, F., & Payrastre, B. (2005) · Blood · doi:10.1182/blood-2004-06-2494 · Cited by 296
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2319 · Cited by 291
Yanada, M., Matsuo, K., Suzuki, T., Kiyoi, H., & Naoe, T. (2005) · Leukemia · doi:10.1038/sj.leu.2403838 · Cited by 289
Ito, K., Nakazato, T., Yamato, K., Miyakawa, Y., Yamada, T., Hozumi, N., Segawa, K., Ikeda, Y., & Kizaki, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1670 · Cited by 287
Physiological functions of protein kinase B/Akt
Yang, Z.-Z., Tschopp, O., Baudry, A., Dümmler, B., Hynx, D., & Hemmings, B. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320350 · Cited by 283
Grandage, V. L., Gale, R. E., Linch, D. C., & Khwaja, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403653 · Cited by 281
Dahia, P. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.185 · Cited by 274
mTOR integrates amino acid- and energy-sensing pathways
Tokunaga, C., Yoshino, K.-I., & Yonezawa, K. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.07.019 · Cited by 268
Choudhary, C., Schwäble, J., Brandts, C., Tickenbrock, L., Sargin, B., Kindler, T., Fischer, T., Berdel, W. E., Müller-Tidow, C., & Serve, H. (2005) · Blood · doi:10.1182/blood-2004-07-2942 · Cited by 263
Chun, K.-H., Kosmeder, J. W., Sun, S., Pezzuto, J. M., Lotan, R., Hong, W. K., & Lee, H.-Y. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.4.291 · Cited by 255
Sujobert, P. (2005) · Blood · doi:10.1182/blood-2004-08-3225 · Cited by 245
Hsp90 and Cdc37 – a chaperone cancer conspiracy
Pearl, L. H. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.011 · Cited by 242
Small-molecule cyclin-dependent kinase modulators
Senderowicz, A. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206954 · Cited by 236
Nuclear Factor-κB Activation: A Question of Life or Death
Shishodia, S., & Aggarwal, B. B. (2002) · BMB Reports · doi:10.5483/bmbrep.2002.35.1.028 · Cited by 236
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Luo, Y., Shoemaker, A. R., Liu, X., Woods, K. W., Thomas, S. A., de Jong, R., Han, E. K., Li, T., Stoll, V. S., Powlas, J. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0005 · Cited by 232
Nuclear factor-κB: a friend or a foe in cancer?
Shishodia, S., & Aggarwal, B. B. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.04.026 · Cited by 228
Brandts, C. H., Sargin, B., Rode, M., Biermann, C., Lindtner, B., Schwäble, J., Buerger, H., Müller-Tidow, C., Choudhary, C., McMahon, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0422 · Cited by 212
AKT crystal structure and AKT-specific inhibitors
Kumar, C. C., & Madison, V. (2005) · Oncogene · doi:10.1038/sj.onc.1209087 · Cited by 206
Constitutive activation of the Wnt/β-catenin signalling pathway in acute myeloid leukaemia
Simon, M., Grandage, V. L., Linch, D. C., & Khwaja, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208431 · Cited by 206
Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)
Sato, S., Fujita, N., & Tsuruo, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205225 · Cited by 206
Thompson, J. E., & Thompson, C. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.103 · Cited by 206
Mechanisms by which IGF-I May Promote Cancer
Grimberg, A. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.6.678 · Cited by 204
AKT/PKB signaling mechanisms in cancer and chemoresistance
Kim, D. (2005) · Frontiers in Bioscience · doi:10.2741/1592 · Cited by 204
Guo, F., Sigua, C., Tao, J., Bali, P., George, P., Li, Y., Wittmann, S., Moscinski, L., Atadja, P., & Bhalla, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2629 · Cited by 202
The AKT kinase is activated in multiple myeloma tumor cells
Hsu, J.-H., Shi, Y., Krajewski, S., Renner, S., Fisher, M., Reed, J. C., Franke, T. F., & Lichtenstein, A. (2001) · Blood · doi:10.1182/blood.v98.9.2853 · Cited by 196
Rahmani, M., Reese, E., Dai, Y., Bauer, C., Payne, S. G., Dent, P., Spiegel, S., & Grant, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2440 · Cited by 195
Zhao, W., Kitidis, C., Fleming, M. D., Lodish, H. F., & Ghaffari, S. (2006) · Blood · doi:10.1182/blood-2005-06-2516 · Cited by 193
Min, Y. H., Eom, J. I., Cheong, J. W., Maeng, H. O., Kim, J. Y., Jeung, H. K., Lee, S. T., Lee, M. H., Hahn, J. S., & Ko, Y. W. (2003) · Leukemia · doi:10.1038/sj.leu.2402874 · Cited by 192
Granville, C. A., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1654 · Cited by 181
DeFeo-Jones, D., Barnett, S. F., Fu, S., Hancock, P. J., Haskell, K. M., Leander, K. R., McAvoy, E., Robinson, R. G., Duggan, M. E., Lindsley, C. W., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.271.4.2 · Cited by 173
Martelli, A. M., Tazzari, P. L., Tabellini, G., Bortul, R., Billi, A. M., Manzoli, L., Ruggeri, A., Conte, R., & Cocco, L. (2003) · Leukemia · doi:10.1038/sj.leu.2403044 · Cited by 172
Self-citationRegulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Sawyer, C., Sturge, J., Bennett, D. C., O’Hare, M. J., Allen, W. E., Bain, J., Jones, G. E., & Vanhaesebroeck, B. (2003) · PubMed · Cited by 169
The Caspase-8 Modulator c-FLIP
Kataoka, T. (2005) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v25.i1.30 · Cited by 167
NF- B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome
Braun, T., Carvalho, G., Coquelle, A., Vozenin, M.-C., Lepelley, P., Hirsch, F., Kiladjian, J.-J., Ribrag, V., Fenaux, P., & Kroemer, G. (2005) · Blood · doi:10.1182/blood-2005-05-1989 · Cited by 166
mTOR regulates cell survival after etoposide treatment in primary AML cells
Xu, Q., Thompson, J. E., & Carroll, M. P. (2005) · Blood · doi:10.1182/blood-2004-11-4468 · Cited by 165
Smith, M., Barnett, M., Bassan, R., Gatta, G., Tondini, C., & Kern, W. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.11.002 · Cited by 162
Crul, M., Rosing, H., de Klerk, G. J., Dubbelman, R., Traiser, M., Reichert, S., Knebel, N. G., Schellens, J. H. M., Beijnen, J. H., & ten Bokkel Huinink, W. W. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00127-2 · Cited by 161
Sampath, D., Cortes, J., Estrov, Z., Du, M., Shi, Z., Andreeff, M., Gandhi, V., & Plunkett, W. (2005) · Blood · doi:10.1182/blood-2005-08-3351 · Cited by 160
Zhao, S., Konopleva, M. Y., Cabreira-Hansen, M. D. G., Xie, Z., Hu, W. S., Milella, M., Estrov, Z. E., Mills, G. B., & Andreeff, M. (2003) · Leukemia · doi:10.1038/sj.leu.2403220 · Cited by 158
Van Ummersen, L., Binger, K., Volkman, J., Marnocha, R., Tutsch, K., Kolesar, J., Arzoomanian, R., Alberti, D., & Wilding, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0406 · Cited by 158
Ihle, N. T., Paine-Murrieta, G., Berggren, M. I., Baker, A., Tate, W. R., Wipf, P., Abraham, R. T., Kirkpatrick, D. L., & Powis, G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0149 · Cited by 151
Shetty, S., Graham, B. A., Brown, J. G., Hu, X., Vegh-Yarema, N., Harding, G. A., Paul, J. T., & Gibson, S. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5404-5416.2005 · Cited by 150
Brozovic, A., Fritz, G., Christmann, M., Zisowsky, J., Jaehde, U., Osmak, M., & Kaina, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20522 · Cited by 146
Birkenkamp, K. U., Geugien, M., Schepers, H., Westra, J. M., Lemmink, H. H., & Vellenga, E. (2003) · Leukemia · doi:10.1038/sj.leu.2403145 · Cited by 146
Shih, L.-Y., Huang, C.-F., Wang, P.-N., Jh, W., Lin, T.-L., Dunn, P., & Kuo, M.-C. (2004) · Leukemia · doi:10.1038/sj.leu.2403274 · Cited by 145
Regulation of the Akt kinase by interacting proteins
Du, K., & Tsichlis, P. N. (2005) · Oncogene · doi:10.1038/sj.onc.1209099 · Cited by 144
Takada, Y., Andreeff, M., & Aggarwal, B. B. (2005) · Blood · doi:10.1182/blood-2004-12-4589 · Cited by 143
Castillo, S. S., Brognard, J., Petukhov, P. A., Zhang, C., Tsurutani, J., Granville, C. A., Li, M., Jung, M., West, K. A., Gills, J. G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1530 · Cited by 143
Frelin, C. (2004) · Blood · doi:10.1182/blood-2004-04-1463 · Cited by 142
Carter, B. Z., Kornblau, S. M., Tsao, T., Wang, R., Schober, W. D., Milella, M., Sung, H., Reed, J. C., & Andreeff, M. (2003) · Blood · doi:10.1182/blood-2003-03-0960 · Cited by 141
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
Horton, T. M., Gannavarapu, A., Blaney, S. M., D’Argenio, D. Z., Plon, S. E., & Berg, S. L. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0135-z · Cited by 139
Warner, J. K., Wang, J. C. Y., Takenaka, K., Doulatov, S. R., McKenzie, J. L., Harrington, L. A., & Dick, J. E. (2005) · Leukemia · doi:10.1038/sj.leu.2403917 · Cited by 137
Death to the bad guys: Targeting cancer via Apo2L/TRAIL
Bouralexis, S., Findlay, D. M., & Evdokiou, A. (2005) · APOPTOSIS · doi:10.1007/s10495-005-6060-0 · Cited by 136
Arden, K. C., & Biggs, W. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00207-2 · Cited by 136
de Toni, F., Racaud‐Sultan, C., Chicanne, G., Mas, V. M., Cariven, C., Briand‐Mésange, F., Salles, J., Demur, C., Allouche, M., Payrastre, B., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209346 · Cited by 134
Noguera, N. I., Ammatuna, E., Zangrilli, D., Lavorgna, S., Divona, M., Buccisano, F., Amadori, S., Mecucci, C., Falini, B., & Lo‐Coco, F. (2005) · Leukemia · doi:10.1038/sj.leu.2403846 · Cited by 132
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Riccioni, R., Pasquini, L., Mariani, G., Saulle, E., Rossini, A., Diverio, D., Pelosi, E., Vitale, A., Chierichini, A., Cedrone, M., et al. (2005) · PubMed · Cited by 132
Hypoxia inducible factor-1: a novel target for cancer therapy
Belozerov, V. E., & Meir, E. G. V. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000180116.85912.69 · Cited by 128
Scheijen, B., Ngo, H. T., Kang, H. K., & Griffin, J. D. (2004) · Oncogene · doi:10.1038/sj.onc.1207456 · Cited by 128
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia
Luo, J.-M., Yoshida, H., Komura, S., Ohishi, N., Pan, L., Shigeno, K., Hanamura, I., Miura, K., Iida, S., Ueda, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402725 · Cited by 127
George, P., Bali, P., Cohen, P. S., Tao, J., Guo, F., Sigua, C. A., Vishvanath, A., Fiskus, W. C., Scuto, A., Annavarapu, S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0006 · Cited by 127
Mammalian Target of Rapamycin Inhibition
Dutcher, J. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050008 · Cited by 126
Phosphoinositide 3-kinase γ: a key modulator in inflammation and allergy
Wymann, M. P., Björklöf, K., Calvez, R., Finan, P. M., Thomast, M., Trifilieff, A., Barbier, M., Altruda, F., Hirsch, E., & Laffargue, M. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310275 · Cited by 126
Komander, D., Kular, G. S., Jennifer, B. A. I. N., Elliott, M., Alessi, D. R., & van Aalten, D. M. F. (2003) · Biochemical Journal · doi:10.1042/bj20031119 · Cited by 126
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
Mesa, R. A., Loegering, D. A., Powell, H. L., Flatten, K. S., Arlander, S. J. H., Dai, N. T., Heldebrant, M. P., Vroman, B. T., Smith, B. D., Karp, J. E., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3523 · Cited by 121
Wnt Signaling: Physiology and Pathology
Prunier, C., Hocevar, B. A., & Howe, P. H. (2004) · Growth Factors · doi:10.1080/08977190410001720860 · Cited by 120
Xu, R., Pelicano, H., Zhang, H., Giles, F. J., Keating, M. J., & Huang, P. (2005) · Leukemia · doi:10.1038/sj.leu.2403968 · Cited by 119
Phosphoinositide 3-kinases as drug targets in cancer
Stephens, L., WILLIAMS, R., & Hawkins, P. T. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.002 · Cited by 115
Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction
Tickenbrock, L., Schwäble, J., Wiedehage, M., Steffen, B., Sargin, B., Choudhary, C., Brandts, C., Berdel, W. E., Müller‐Tidow, C., & Serve, H. L. (2005) · Blood · doi:10.1182/blood-2004-07-2924 · Cited by 112
Choi, Y., Zhang, J., Murga, C., Yu, H., Koller, E., Monia, B. P., Gutkind, J. S., & Li, W. (2002) · Oncogene · doi:10.1038/sj.onc.1205650 · Cited by 108
Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors
Minami, Y., Kiyoi, H., Yamamoto, Y., Yamamoto, K., Ueda, R., Saito, H., & Naoe, T. (2002) · Leukemia · doi:10.1038/sj.leu.2402558 · Cited by 107
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia
Carter, B. Z., Milella, M., Tsao, T., McQueen, T. J., Schober, W. D., Hu, W., Dean, N. M., Steelman, L. S., McCubrey, J. A., & Andreeff, M. (2003) · Leukemia · doi:10.1038/sj.leu.2403113 · Cited by 107
Min, Y. H., Cheong, J., Kim, J. Y., Eom, J.-I., Lee, S., Hahn, J. S., Ko, Y. W., & Lee, M. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0174 · Cited by 107
Novel targets of Akt, p21, and MDM2
Zhou, B. P., & Hung, M. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70128-0 · Cited by 105
Myklebust, J. H., Blomhoff, H. K., Rusten, L. S., Stokke, T., & Smeland, E. B. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00868-8 · Cited by 103
Liu, W., Akhand, A. A., Takeda, K., Kawamoto, Y., Itoigawa, M., Kato, M., Suzuki, H., Ishikawa, N., & Nakashima, I. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401238 · Cited by 103
Bortul, R., Tazzari, P. L., Cappellini, A., Tabellini, G., Billi, A. M., Bareggi, R., Manzoli, L., Cocco, L., & Martelli, A. M. (2003) · Leukemia · doi:10.1038/sj.leu.2402793 · Cited by 102
Self-citationThe complexity of PTEN: mutation, marker and potential target for therapeutic intervention
Steelman, L. S., Bertrand, F. E., & McCubrey, J. A. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.6.537 · Cited by 102
Nyåkern, M., Tazzari, P. L., Finelli, C., Bosi, C., Follo, M. Y., Grafone, T., Piccaluga, P. P., Martinelli, G., Cocco, L., & Martelli, A. M. (2005) · Leukemia · doi:10.1038/sj.leu.2404057 · Cited by 99
Self-citationThe termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases
Backers, K., Bléro, D., Paternotte, N., Zhang, J., & Erneux, C. (2003) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(02)00043-2 · Cited by 98
Kohl, T. M., Schnittger, S., Ellwart, J. W., Hiddemann, W., & Spiekermann, K. (2005) · Blood · doi:10.1182/blood-2004-06-2068 · Cited by 97
Yu, C., Rahmani, M., Dai, Y., Conrad, D. H., Krystal, G. W., Dent, P., & Grant, S. (2003) · PubMed · Cited by 97
Nanri, T., Matsuno, N., Kawakita, T., Suzushima, H., Kawano, F., Mitsuya, H., & Asou, N. (2005) · Leukemia · doi:10.1038/sj.leu.2403803 · Cited by 94
STAT3 activation is required for Asp816 mutant c-Kit induced tumorigenicity
Ning, Z.-Q., Li, J., McGuinness, M., & Arceci, R. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204590 · Cited by 94
Acute promyelocytic leukemia: where does it stem from?
Grimwade, D. J., & Enver, T. (2004) · Leukemia · doi:10.1038/sj.leu.2403234 · Cited by 94
Cappellini, A., Tabellini, G., Zweyer, M., Bortul, R., Tazzari, P. L., Billi, A. M., Falà, F., Cocco, L., & Martelli, A. M. (2003) · Leukemia · doi:10.1038/sj.leu.2403111 · Cited by 94
Self-citationRamos, A. M., Fernández, C., Amrán, D., Sancho, P., de Blas, E., & Aller, P. (2005) · Blood · doi:10.1182/blood-2004-07-2802 · Cited by 94
Class I phosphoinositide 3-kinases
Anderson, K. E., & Jackson, S. P. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00270-4 · Cited by 93
Characterization of the Murine Immunological Signaling Network with Phosphospecific Flow Cytometry
Krutzik, P. O., Hale, M. B., & Nolan, G. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2366 · Cited by 93
Converging pathways in leukemogenesis and stem cell self-renewal
Moore, M. A. S. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.04.011 · Cited by 92
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia
Larizza, L., Magnani, I., & Beghini, A. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400007565 · Cited by 91
Geddis, A. E., Fox, N. E., & Kaushansky, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105178200 · Cited by 90
Acute promyelocytic leukemia: PML/RARα and the leukemic stem cell
Puccetti, E., & Ruthardt, M. (2004) · Leukemia · doi:10.1038/sj.leu.2403367 · Cited by 89
Borgatti, P., Martelli, A. M., Tabellini, G., Bellacosa, A., Capitani, S., & Neri, L. M. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10279 · Cited by 88
Self-citationIncreased IκB kinase activity is associated with activated NF-κB in acute myeloid blasts
Baumgartner, B., Weber, M., Quirling, M., Fischer, C., Page, S., Adam, M., von Schilling, C., Waterhouse, C., Schmid, C., Neumeier, D., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402641 · Cited by 88
Crosstalk between angiogenesis and lymphangiogenesis in tumor progression
Scavelli, C., Vacca, A., Pietro, G. D., Dammacco, F., & Ribatti, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403355 · Cited by 87
O'Gorman, D., McKenna, S. L., McGahon, A. J., Knox, K., & Cotter, T. G. (2000) · Leukemia · doi:10.1038/sj.leu.2401726 · Cited by 86
Schwäble, J., Choudhary, C., Thiede, C., Tickenbrock, L., Sargin, B., Steur, C., Rehage, M., Rudat, A., Brandts, C., Berdel, W. E., et al. (2004) · Blood · doi:10.1182/blood-2004-03-0940 · Cited by 83
Minami, Y., Yamamoto, K., Kiyoi, H., Ueda, R., Saito, H., & Naoe, T. (2003) · Blood · doi:10.1182/blood-2002-12-3813 · Cited by 81
Cheong, J., Eom, J.-I., Maeng, H. M., Lee, S., Hahn, J. S., Ko, Y. W., & Min, Y. H. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04452.x · Cited by 81
Neri, L. M., Borgatti, P., Tazzari, P. L., Bortul, R., Cappellini, A., Tabellini, G., Bellacosa, A., Capitani, S., & Martelli, A. M. (2003) · PubMed · Cited by 81
Self-citationPI‐3K/Akt and NF‐κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment
Zauli, G., Sancilio, S., Cataldi, A., Sabatini, N., Bosco, D., & Pietro, R. D. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20202 · Cited by 79
Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Sanz, M. Á., Fenaux, P., & Lo‐Coco, F. (2005) · PubMed · Cited by 79
van der Kolk, D. M., de Vries, E., Noordhoek, L., van den Berg, E., van der Pol, M., Müller, M. M., & Vellenga, E. (2001) · Leukemia · doi:10.1038/sj.leu.2402236 · Cited by 79
Gupta, P., Niehans, G. A., LeRoy, S., Gupta, K., Morrison, V., Schultz, C. L., Knapp, D., & Kratzke, R. (1999) · Leukemia · doi:10.1038/sj.leu.2401233 · Cited by 78
Ghaffari, S., Kitidis, C., Zhao, W., Marinković, D., Fleming, M. D., Luo, B., Marszalek, J. R., & Lodish, H. F. (2005) · Blood · doi:10.1182/blood-2005-06-2304 · Cited by 76
p-Glycoprotein-Mediated Transport of a Fluorescent Rapamycin Derivative in Renal Proximal Tubule
Miller, D. S., Fricker, G., & Drewe, J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36817-x · Cited by 74
Gutiérrez, N. C., López-Pérez, R., Hernández, J. M., Isidro, I., González, B., Delgado, M., Fermiñán, E., García, J. L., Vázquez, L., González, M., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403625 · Cited by 71
Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders
Aggerholm, A., Grønbæk, K., Guldberg, P., & Hokland, P. (2000) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2000.90181.x · Cited by 69
Unanswered questions in acute myeloid leukaemia
Ferrara, F. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01512-8 · Cited by 68
Dai, Y., Rahmani, M., Pei, X., Khanna, P., Han, S. I., Mitchell, C., Dent, P., & Grant, S. (2004) · Blood · doi:10.1182/blood-2004-07-2767 · Cited by 66
List, A. F., Glinsmann‐Gibson, B., Stadheim, C., Meuillet, E. J., Bellamy, W. T., & Powis, G. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.03.005 · Cited by 63
Hahn, M., Li, W., Yu, C., Rahmani, M., Dent, P., & Grant, S. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0137 · Cited by 63
van Stijn, A., van der Pol, M. A., Kok, A., Bontje, P. M., Roemen, G. M. J. M., Beelen, R. H. J., Ossenkoppele, G. J., & Schuurhuis, G. J. (2003) · PubMed · Cited by 61
Cited by
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
Self-citationDubrovska, A., Kim, S., Salamone, R. J., Walker, J. R., Maira, S.-M., García-Echeverría, C., Schultz, P. G., & Reddy, V. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810956106 · Cited by 564
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S., Abrams, S. L., Whelan, J., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.26 · Cited by 385
Self-citationContribution of bone microenvironment to leukemogenesis and leukemia progression
Ayala, F., Dewar, R., Kieran, M., & Kalluri, R. (2009) · Leukemia · doi:10.1038/leu.2009.175 · Cited by 273
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
Kharas, M. G., Okabe, R., Ganis, J. J., Gozo, M., Khandan, T., Paktinat, M., Gilliland, D. G., & Gritsman, K. (2010) · Blood · doi:10.1182/blood-2009-06-229443 · Cited by 272
Metadata
- Authors
- Martelli, A. M., Nyåkern, M., Tabellini, G., Bortul, R., Tazzari, P. L., Evangelisti, C., & Cocco, L.
- Venue
- Leukemia
- Published
- 2006-04-27
- Volume
- 20
- Issue
- 6
- Pages
- 911-928
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W1974300980
- Cited by
- 342
- References
- 233
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.